Mirum Pharmaceuticals (NASDAQ:MIRM) Rating Lowered to Strong Sell at BidaskClub

BidaskClub lowered shares of Mirum Pharmaceuticals (NASDAQ:MIRM) from a sell rating to a strong sell rating in a report published on Friday morning, BidAskClub reports.

A number of other equities analysts have also commented on MIRM. HC Wainwright restated a buy rating and issued a $52.00 price target on shares of Mirum Pharmaceuticals in a research report on Thursday, September 3rd. Raymond James upgraded shares of Mirum Pharmaceuticals from an outperform rating to a strong-buy rating and upped their target price for the stock from $28.00 to $48.00 in a research report on Friday, August 7th. Piper Sandler started coverage on shares of Mirum Pharmaceuticals in a research report on Thursday, July 30th. They set an overweight rating on the stock. ValuEngine lowered shares of Mirum Pharmaceuticals from a buy rating to a hold rating in a research report on Monday, July 20th. Finally, Citigroup upped their target price on shares of Mirum Pharmaceuticals from $28.00 to $31.00 and gave the stock a buy rating in a research report on Tuesday, September 1st. One analyst has rated the stock with a sell rating, two have issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of Buy and an average target price of $36.33.

NASDAQ:MIRM opened at $17.14 on Friday. The firm has a market cap of $435.34 million, a PE ratio of -5.01 and a beta of 2.22. Mirum Pharmaceuticals has a 12 month low of $6.51 and a 12 month high of $28.31. The company’s 50-day moving average price is $19.54 and its two-hundred day moving average price is $19.39.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.93) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.87) by ($0.06). Analysts expect that Mirum Pharmaceuticals will post -3.77 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Chartwell Investment Partners LLC bought a new stake in shares of Mirum Pharmaceuticals during the second quarter worth approximately $333,000. New York State Common Retirement Fund raised its stake in shares of Mirum Pharmaceuticals by 93.1% during the second quarter. New York State Common Retirement Fund now owns 3,112 shares of the company’s stock worth $61,000 after buying an additional 1,500 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Mirum Pharmaceuticals by 38.4% during the second quarter. Charles Schwab Investment Management Inc. now owns 15,333 shares of the company’s stock worth $299,000 after buying an additional 4,255 shares during the last quarter. Wells Fargo & Company MN raised its stake in shares of Mirum Pharmaceuticals by 1,465.1% during the first quarter. Wells Fargo & Company MN now owns 3,678 shares of the company’s stock worth $51,000 after buying an additional 3,443 shares during the last quarter. Finally, Squarepoint Ops LLC bought a new stake in shares of Mirum Pharmaceuticals during the first quarter worth approximately $488,000. 74.08% of the stock is owned by institutional investors and hedge funds.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC).

See Also: What are no-load funds?

Analyst Recommendations for Mirum Pharmaceuticals (NASDAQ:MIRM)

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.